دورية أكاديمية
أعرض في EDS

The survival prediction of advanced colorectal cancer received neoadjuvant therapy-a study of SEER database.

التفاصيل البيبلوغرافية
العنوان: The survival prediction of advanced colorectal cancer received neoadjuvant therapy-a study of SEER database.
المؤلفون: Han Z; Department of General Surgery, Tangdu Hospital, The Air Force Medical University, Xi'an, 710038, China., Yang H; Department of General Surgery, Tangdu Hospital, The Air Force Medical University, Xi'an, 710038, China., Qiao Q; Department of General Surgery, Tangdu Hospital, The Air Force Medical University, Xi'an, 710038, China., Wu T; Department of General Surgery, Tangdu Hospital, The Air Force Medical University, Xi'an, 710038, China., He X; Department of General Surgery, Tangdu Hospital, The Air Force Medical University, Xi'an, 710038, China., Wang N; Department of General Surgery, Tangdu Hospital, The Air Force Medical University, Xi'an, 710038, China. wangnanafmu@163.com.
المصدر: World journal of surgical oncology [World J Surg Oncol] 2024 Jul 01; Vol. 22 (1), pp. 175. Date of Electronic Publication: 2024 Jul 01.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101170544 Publication Model: Electronic Cited Medium: Internet ISSN: 1477-7819 (Electronic) Linking ISSN: 14777819 NLM ISO Abbreviation: World J Surg Oncol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : BioMed Central, 2003-
مواضيع طبية MeSH: Colorectal Neoplasms*/pathology , Colorectal Neoplasms*/mortality , Colorectal Neoplasms*/therapy , SEER Program*/statistics & numerical data , Neoadjuvant Therapy*/statistics & numerical data , Neoadjuvant Therapy*/methods , Neoadjuvant Therapy*/mortality , Nomograms*, Humans ; Male ; Female ; Middle Aged ; Survival Rate ; Follow-Up Studies ; Prognosis ; Aged ; Lymphatic Metastasis ; Neoplasm Staging ; Adult ; Retrospective Studies
مستخلص: Purpose: The aim of study was to screen factors associated with the overall survival of colorectal cancer patients with lymph nodes metastasis who received neoadjuvant therapy and construct a nomogram model.
Methods: All enrolled subjects of the SEER database were randomly assigned to the training and testing group in a ratio of 3:2. The patients of Tangdu Hospital were seemed as validation group. Univariate cox regression analysis, lasso regression and random forest survival were used to screen variables related to the survival of advanced CRC patients received neoadjuvant therapy in the training group. Area under curves were adopted to evaluate the 1,3,5-year prediction value of the optimal model in three cohorts. Calibration curves were drawn to observe the prediction accuracy of the nomogram model. Decision curve analysis was used to assess the potential clinical value of the nomogram model.
Results: A total of 1833 subjects were enrolled in this study. After random allocation, 1055 cases of the SEER database served as the training group, 704 cases as the testing group and 74 patients from our center as the external validation group. Variables were screened by univariate cox regression used to construct a nomogram survival prediction model, including M, age, chemotherapy, CEA, perineural invasion, tumor size, LODDS, liver metastasis and radiation. The AUCs of the model for predicting 1-year OS in the training group, testing and validation group were 0.765 (0.703,0.827), 0.772 (0.697,0.847) and 0.742 (0.601,0.883), predicting 3-year OS were 0.761 (0.725,0.780), 0.742 (0.699,0.785), 0.733 (0.560,0.905) and 5-year OS were 0.742 (0.711,0.773), 0.746 (0.709,0.783), 0.838 (0.670,0.980), respectively. The calibration curves showed the difference between prediction probability of the model and the actual survival was not significant in three cohorts and the decision curve analysis revealed the practice clinical application value. And the prediction value of model was better for young CRC than older CRC patients.
Conclusion: A nomogram model including LODDS for the prognosis of advanced CRC received neoadjuvant therapy was constructed and verified based on the SEER database and single center practice. The accuracy and potential clinical application value of the model performed well, and the model had better predictive value for EOCRC than LOCRC.
(© 2024. The Author(s).)
References: N Engl J Med. 2006 Sep 14;355(11):1114-23. (PMID: 16971718)
Ann Surg. 2020 Mar;271(3):440-448. (PMID: 31318794)
Tumori. 2017 Jan 21;103(1):87-92. (PMID: 27716883)
Int J Colorectal Dis. 2023 Jul 11;38(1):192. (PMID: 37432563)
Lancet Glob Health. 2018 May;6(5):e555-e567. (PMID: 29653628)
Oncol Lett. 2024 Mar 11;27(5):201. (PMID: 38516687)
BMC Surg. 2022 Jul 4;22(1):256. (PMID: 35787802)
World J Gastrointest Oncol. 2022 Feb 15;14(2):423-433. (PMID: 35317319)
N Engl J Med. 2004 Oct 21;351(17):1731-40. (PMID: 15496622)
Int J Surg. 2016 Aug;32:24-30. (PMID: 27321382)
Chin J Cancer. 2017 Apr 28;36(1):41. (PMID: 28454595)
Gut. 2019 Dec;68(12):2179-2185. (PMID: 31488504)
World J Surg Oncol. 2018 Sep 13;16(1):186. (PMID: 30213260)
EXCLI J. 2022 Jan 07;21:162-182. (PMID: 35221839)
World J Gastroenterol. 2020 Nov 14;26(42):6638-6657. (PMID: 33268952)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Ann Surg Oncol. 2023 Apr;30(4):2458-2468. (PMID: 36575288)
J Cancer. 2020 Jan 16;11(7):1702-1711. (PMID: 32194782)
Br J Surg. 2021 Dec 1;108(12):1417-1425. (PMID: 34694371)
J Natl Compr Canc Netw. 2021 Mar 02;19(3):329-359. (PMID: 33724754)
Eur J Surg Oncol. 2021 Dec;47(12):3175-3181. (PMID: 34120806)
Anticancer Res. 2019 Apr;39(4):2113-2120. (PMID: 30952757)
Ann Oncol. 2023 Jan;34(1):78-90. (PMID: 36220461)
J Natl Compr Canc Netw. 2022 Oct;20(10):1139-1167. (PMID: 36240850)
Dis Colon Rectum. 2021 Oct 1;64(10):1212-1221. (PMID: 34516443)
J Clin Med. 2021 May 28;10(11):. (PMID: 34071492)
J Clin Oncol. 2012 Jun 1;30(16):1926-33. (PMID: 22529255)
Clin Colorectal Cancer. 2021 Mar;20(1):29-41. (PMID: 33531256)
Front Oncol. 2022 Jul 18;12:937114. (PMID: 35928863)
معلومات مُعتمدة: 82072722 National Natural Science Foundation of China
فهرسة مساهمة: Keywords: CRC; LODDS; Neoadjuvant therapy; SEER database; Survival
تواريخ الأحداث: Date Created: 20240702 Date Completed: 20240702 Latest Revision: 20240704
رمز التحديث: 20240704
مُعرف محوري في PubMed: PMC11218294
DOI: 10.1186/s12957-024-03458-7
PMID: 38951795
قاعدة البيانات: MEDLINE
الوصف
تدمد:1477-7819
DOI:10.1186/s12957-024-03458-7